OTC · LCAR
Lescarden Inc.
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Aug 16, 2026, 8:02 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.18K
- P/E ratio
- —
- Dividend yield
- —
- 52-week range
- — – —
- Volume
- 4K
- Avg. volume
- 0
Price performance
LCAR price history
1M range · 0 trading sessions · Daily adjusted prices
LCAR does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest LCAR news
The latest Smart Investors Daily articles mentioning LCAR.
Stock researchCompany · Overview
LCAR research
Overview
Company profile and research snapshot.
Company profile
Lescarden Inc. researches, tests, develops, and sells medications for the control and cure of various diseases in the United States, Europe, and South Korea. Its lead product is Catrix Wound Dressing for the management of chronic lesions and burns, as well as for non-healing wounds, including decubitus ulcers, venous stasis ulcers, and diabetic ulcers. The company also offers a line of Catrix-based wound and skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, it provides nutritional supplements, such as Bio-Cartilage and Poly-NAG, a patented glucosamine polymer; and licenses its technologies for commercialization by other companies. Lescarden Inc. was founded in 1960 and is based in New York, New York.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
